Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources
- 1 June 2003
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 31 (12) , 1105-1117
- https://doi.org/10.1038/sj.bmt.1704105
Abstract
Over the last 15 years, we have performed a total of 30 haematopoietic stem cell transplants on 27 children suffering from Hurler's syndrome. These children were of median age 11 months at the time of diagnosis and 25 months at the time of transplantation. The phenotype was severe in 21 cases (78%). The donor was familial in 13 cases: nine genotypically identical, one phenotypically identical father and three HLA-mismatched donors. Unrelated donors were selected in 17 cases: four phenotypically identical and 13 with 1–4 HLA mismatches. The conditioning regimen generally consisted of busulphan 600 mg/m2 plus cyclophosphamide (Endoxan®) 260 mg/kg and cyclosporin with methotrexate for GvHD prophylaxis. Rabbit anti-thymocyte globulin (Thymoglobuline®) was given for all unrelated or familial mismatched transplantations. The median nucleated cell dose infused was 6.00 108 TNC/kg. No bone marrow (apart from one) was T cell depleted. For first transplants, engraftment was observed in 23/27 patients (pts) (85%). Primary graft failure was observed in 4/27 patients (16%), two were retransplanted from an unrelated donor, one with success. Four patients have died. The primary cause of death was infection in three cases (TRM : 11%) and disease progression in one case, after primary graft failure. Of the 23 living patients, two have disease progression after graft failure and 21 (78%) have functional grafts with a favourable long-term outcome after a median follow-up of 4.7 years, having either full or mixed chimaerism. Among surviving patients with functional grafts, 13 (62%) were transplanted from unrelated donors of whom 10 (77 %) had HLA disparities. There was a remarkably low incidence of GvHD. In our experience, haematopoietic stem cell transplantation using an HLA-matched familial donor or an HLA-matched or -mismatched unrelated donor without T cell depletion or irradiation can achieve a favourable outcome in Hurler's syndrome, with improved cognitive function, but with a limited effect on the corneas and skeleton.Keywords
This publication has 29 references indexed in Scilit:
- Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutationsHuman Genetics, 2001
- Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimensBone Marrow Transplantation, 2001
- Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and -mismatched situationBone Marrow Transplantation, 2000
- An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic diseaseBone Marrow Transplantation, 2000
- Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centresArchives of Disease in Childhood, 1997
- Long‐term outcome of Hurler syndrome following bone marrow transplantationAmerican Journal of Medical Genetics, 1993
- Prenatal diagnosis of Hurler disease by analysis of α‐iduronidase in chorionic villiJournal of Inherited Metabolic Disease, 1991
- DNA typing of DRw6 subtypes: Correlation with DRB1 and DRB3 allelic sequences by hybridization with oligonucleotide probesHuman Immunology, 1989
- A division of HLA-DQw1 associated with DR1, DR1x-DQw1, DR2 short, DRw10, and DRw14. I. Definition by alloantiserum LY1327Human Immunology, 1987
- REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATIONThe Lancet, 1981